5. ● Cancer involves complex multiple heterotypic
interactions.
● Tumor microenvironment or STROMA
influences
1) Growth
2) Ability to progress
3) Metastasise
6.
7. IMMUNE RESPONSE
CHRONIC INFLAMMATION
● Hepatitis B & C lead to hepatic cancer; H Pylori
leading to Gastric Cancer.
● Rudolf Virchow in 1863 linked association of
leukocytes in tumor tissues.
● Experimentally, pro-inflammatory substances
favor tumor growth, angiogenesis and
metastasis.
10. ROLE OF TGF β
● Associated with T Cell suppression and inhibition
of proliferation of lymphocytes.
● Reduces immune cell activation, blocks anti
tumor activity.
● Promotes angiogenesis and over expression
causes abberant extracellular matrix.
● Production tightly regulated in normal cells.
11. COX 2 and Prostaglandin
Synthesis
Chemoprevention strategy
12. CHRONIC INFLAMMATION
● Upregulation of non specific proinflammatory
cytokines.
● Increased conversion of normal cells to pre-
neoplastic foci.
● Gain of function in somatic mutations
transforms cells for tumor initiation.
13. TUMOR ANGIOGENESIS
● Switching on of “angiogenic switch”: balance
between
1) Tumor genes
2) Signals from tumor stroma and recruited
inflammatory cells.
3) Hypoxia
● Endothelial cells are influenced majorly by
Vascular Endothelial Growth Factor (VEGF).
15. Within the tumor stroma
HIF 1α generation.
Normally ubiquitinated by Von Hippel
Lindau (VHL) gene product.
VEGF mRNA is found in
1) Renal Cell Carcinomas
2) Promotes the stem cell multipotency and self renewal.
3) Promotes lymphangiogenesis
22. Switch from E Cadherin to N-cadherin expression (a
Mesenchymal cell marker)
23. Constant interaction between malignantConstant interaction between malignant
Cell and Extracelular MatrixCell and Extracelular Matrix
Constant interaction between malignantConstant interaction between malignant
Cell and Extracelular MatrixCell and Extracelular Matrix
24. Movement is similar
to an inchworm
Focal Adhesion along with
Activation of GTPases and
Actin and Myosin
Contraction
Recruitment of Matrix Metalloproteases to focal adhesion sites;
Degradation of Extracellular Matrix and
Cell glides forward.
25. Disruption of the basement membrane; alteration of balance
Between proteases and their inhibitory proteins.
Collagenases degrade Collagen Type IV;
Releases activated chemokines and other
Bioactive compunds
Increased in cells with metastatic
Potential.
26. INTRAVASATION
● The entry of tumor cells into circulation is
intravasation.
● The exit of tumor cells from circulation is
extravasation.
● Escape easy through abnormal vasculature.
● Chemokines as “attractants” guide cells in
circulation.
28. SURVIVAL IN CIRCULATORY
SYSTEM
Heterotypic Foci; Tumor aggregation with
Coagulation factors.
Homotypic Foci: Tumor aggregation with
Platelets.
Tipping of balance between anti and pro apoptotic pathways; survival of anoikis
29. EXTRAVASATION
1) Increased expression of Cell Adhesion
Molecules
2) VEGF increases vascular permeability
3) Some tumor cells may follow White Blood Cell
motility patterns
30. PROLIFERATION
● Final step; host tissue influences growth by
auto/para/endocrine pathways.
● e.g. Liver synthesises IGF-1 (Insulin Like
Growth Factor) which stimulates cells from
breast, colon and bladder.
● These cells over express receptors for these
ligands.
31. ANGIOGENESIS
● VEGF is well characterised.
● Stimulates endothelial cells; pericytes and
increasing vascular permeability.
● Key molecule for homing of VEGF-R positive
bone marrow derived progenitor cells.
32.
33. Paget's Seed and Soil Hypothesis
Tumors Cells= Seed
Permissive role of environment=Soil.
The hypothesis where cancer cells are able to
survive and proliferate is still the conceptual
model in modern cancer research.
34. Role of Cancer Stem Cells or Cancer Initiating
Cells. (CSC/CIC)
35. PERMISSIVE ROLE OF VEGF-1 BONE
MARROW DERIVED CELLS
● They migrate to colonise target areas.
● Express hematopoietic markers- CD34, CD116,
c-kit, integrins and chemokine receptors.
● Promote homing and attachment to the target
tissue.
36. RECREATE SUPPORTIVE
MICROENVIRONMENT
● Secretion of chemokines + Release of
angiogenic factors (VEGF-A).
● Chemoattractant proteins S100A8 and S100A9
were initially detected.
● Metastatic niches and process has major
clinical implications.
37. THERAPY INDUCED MODIFICATION OF STROMA
IMPACTS TUMOR PROGRESSION
Radiotherapy:
1) Affects tumor stroma
2) Bidirectional cell signalling
3) Stroma exerts tumor promoting effects
● Tumor recurrences in irradiated field have a
poor prognosis.
38. CULPRIT?
● Impaired angiogenic response
● Hypoxia upregulates matricellular protein
CYR61 and integrin άVβ5 mediating survival in
hypoxic conditions.
● Selects hypoxia resistant, invasive and
metastatic phenotype.
39. FURTHER INSULT
● Antiapoptotic factors like IGF and pro
inflammatory cytokines (GM-CSF) are
generated.
● Generation of tumor promoting factors like EGF.
40. INCREASED SURVIVAL OF
CSC/CIC
● Identified by Cluster of Differentiation (CD Number).
● Breast cancer experimental model CD44+/CD24-
shows few or absent double strand breaks.
● CD133+ glioma cell lines is more resistant as
compared to CD133- lines.
● Radio Resistance= efficient repair.
42. 1) PERMISSIVE ROLE OF TGF-β
Prime role identified in :
● Suppression of host immune responses
● Augments angiogenesis.
Inactivating mutations of TGFβ2 are infrequent.
TGFβ antisense compound AP12009 targets
mRNA; reduces cell proliferation in all glioma cell
lines.
Hau P et al. Oligonucleotides 17;201-212, 2007
43. ● Phase I/II clinical data.
● Reported proonged survival compared with
literature data.
● Observed time course are consistent with
proposed reversal of tumor induced
immunosupression.
44. THERAPEUTIC INHIBITION OF
VASCULOGENESIS
● Bevacizumab: Humanised monoclonal antibody inhibits VEGF.
● Phase II trials with bevacizumab and irinotecan resulted in radiologic
response of 47% to 67% and 6- month survival of 62% to 77%.
● Phase II study for combination of TMZ & Bevacizumab showed
radiological responses in 13/14 assessable patients.
● 1 year PFS and OS were 59.3% and 86.7% respectively.
Narayana A et al. J Neurosurg 110:173-180, 2009 and IJORBP 72:383-389, 2008.
Chen et al. JCO 25:4714-4721, 2007.
45. ● Although impressive results; 70% patients recur
locally; 30% recurred as extensive gliomatosis.
● Biopsy correlation showed invasive
mesenchymal phenotype.
● Blocking VEGF results in angiogenic
independent GBM stem cell growth with
upregulation of proinvasive genes.
Sakariassen et al. Proc Natl Acad Sci USA 101:16466-16471,2006
46. ● Interesting aspect of Lithium used for bipolar
disorders.
● Inhibits migration of glioblastoma cells; inhibits
GSK 3 protein regulating metabolism, cell
division and death.
● Phase II multi institutional trial of Lithium, TMZ
and Bevacizumab is proposed.
47. HYPOXIA
● HIF 1α upregulates invasive genotype: CXCR4, SDF-
1(ligand of CXCR4), VEGF and MMP.
● SDF-1 exerts proliferative, anti apoptotic, and
chemotactic effects on glioma cell lines in vitro.
● Promotes glioma cell line invasion by recruitment of
MMP.
● Attractive targets for future therapy to prevent
invasion.
49. RADIATION INDUCED TGF-β
● Reactive Oxygen Species promotes generation of
TGF-β by LAP (latency Associated Peptide)
complex by conformational change.
● Inhibits DNA Repair genes; blunts ATM identified
radiation damaged DNA strand breaks.
● Inhibitor to TGF causes reduced invasiveness and
potentially increase effectiveness of external
radiation.
50. SEED AND SOIL REVISITED
● Glioblastoma is like pulled out weed; but soil
still remains hospitable to scattered seeds.
● Therapy by itself affects the microenvironment.
● Potentially blocking the deleterious effect of
cytokine cascade would limit toxicity and
protect normal brain function.